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Background and purpose: Sex and race disparities in recombinant tissue plasminogen 
activator (rt-PA) use have been reported. We sought to explore sex and race differences 
in the utilization of rt-PA at primary stroke centers (PSCs) compared to non-PSCs across 
the US.
Methods: Data from the National (Nationwide) Inpatient Sample (NIS) 2004–2010 was 
utilized to assess sex differences in treatment for ischemic stroke in PSCs compared to 
non-PSCs.
results: There were 304,152 hospitalizations with a primary diagnosis of ischemic 
stroke between 2004 and 2010 in the analysis: 75,160 (24.7%) patients were evalu-
ated at a PSC. A little over half of the patients evaluated at PSCs were female (53.8%). 
A lower proportion of women than men received rt-PA at both PSCs (6.8 vs. 7.5%, 
p < 0.001) and non-PSCs (2.3 vs. 2.8%, p < 0.001). After adjustment for potential con-
founders the odds of being treated with rt-PA remained lower for women regardless 
of presentation to a PSC (OR 0.87, 95% CI 0.81–0.94) or non-PSC (OR 0.88, 95% CI 
0.82–0.94). After stratifying by sex and race, the lowest absolute treatment rates were 
observed in black women (4.4% at PSC, 1.9% at non-PSC). The odds of treatment, 
relative to white men, was however lowest for white women (PSC OR = 0.85, 95% 
CI 0.78–0.93; non-PSC OR = 0.80, 95% CI 0.75–0.85). In the multivariable model, 
sex did not modify the effect of PSC certification on rt-PA utilization (p-value for 
interaction = 0.58).
conclusion: Women are less likely to receive rt-PA than men at both PSCs and non-
PSCs. Absolute treatment rates are lowest in black women, although the relative differ-
ence in men and women was greatest for white women.
Keywords: acute stroke care, thrombolysis, health policy, emergency care, healthcare delivery systems
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inTrODUcTiOn
Intravenous recombinant tissue plasminogen activator (IV rt-PA) 
is a thrombolytic agent that improves outcomes in stroke patients 
when administered within 4.5 h of symptom onset (1–3). The 
utilization of this therapy in the United States is low despite 
consensus guidelines recommending its use (4, 5). Although 
patient-level factors, primarily a delay from symptom onset to 
emergency department arrival, are a major contributor to the 
low utilization of IV rt-PA, provider- and hospital-level factors 
may also contribute to underutilization. The Joint Commission 
(TJC) primary stroke center (PSC) certification, which requires 
an acute stroke team, a stroke unit, and written care protocols, 
has been associated with higher rt-PA utilization and lower 
mortality among patients when compared to patients treated at 
non-PSCs (6–10).
Sex disparities in IV rt-PA use have been reported; however, 
whether PSCs reduce these disparities is unknown (11–13). 
Given this, an analysis of IV rt-PA treatment comparing non-
PSCs and PSCs across the US would fill a gap in our understand-
ing. When compared with men, women have worse functional 
outcomes and lower quality of life after stroke (14, 15). While 
this may be attributable to patient-level factors, such as older 
age at time of stroke or differences in stroke subtype, there is 
also evidence that women receive lower quality of care than 
men, with less efficient stroke evaluation, delay in treatment 
with thrombolytics, and lower adherence to stroke care quality 
metrics (16–18).
Further contributing to the sex disparity in IV rt-PA utilization 
is evidence that sex differences may vary by race/ethnicity, with 
black women being treated less frequently than white women 
(19). Building on prior work evaluating differences in rt-PA by 
race/ethnicity (20), we used the National (Nationwide) Inpatient 
Sample (NIS), to explore differences in the utilization of rt-PA 
at PSCs compared to non-PSCs, stratified by both sex and race/
ethnicity.
MaTerials anD MeThODs
study Design
A retrospective, cross-sectional analysis of data from the NIS 
from 2004 to 2010 was conducted. As part of the Agency 
for Healthcare Research and Quality’s Healthcare Cost and 
Utilization Project, the NIS is the largest publicly available all-
payer inpatient care database (21). This analysis limits the data 
to 26 states that publicly identified both treating hospital and 
patient race/ethnicity (Table S1 in Supplementary Material). 
Data on PSC certification and date of initial certification for 
PSCs was obtained via personal communication from TJC on 
May 17th, 2011 (Jean Range, executive director of disease spe-
cific care, TJC, unpublished data, 2011). Methods for this work 
have been previously reported (7, 20).
We identified patients aged ≥18 years who had a primary diag-
nosis of ischemic stroke defined by International Classification 
of Diseases, 9th Revision (ICD-9) codes 433.x1, 434.x1, and 436. 
The positive predictive value of these codes for identifying acute 
ischemic stroke is greater than 85% (22). We excluded patients 
transferred from other hospitals. Patients who were missing 
information on death, sex, length of stay, or primary payer were 
excluded. Treatment with IV rt-PA, defined by ICD-9 procedure 
code 99.10, was the primary outcome. When compared to phar-
macy billing data, this code has been shown to identify 77% of IV 
rt-PA cases (23). This study involved the analysis of de-identified 
data and was exempt from IRB approval.
Demographic Variables
The NIS classifies sex as male or female. Race/ethnicity is reported 
as non-Hispanic white, non-Hispanic black, Hispanic, Asian/
Pacific Islander, Native American, or other. Race and ethnicity are 
not reported separately. Other patient-level variables included age, 
year of discharge, expected primary payer (Medicaid, Medicare, 
private, other), median household income in the patient’s ZIP 
code, comorbid conditions (Table S2 in Supplementary Material) 
(24), and an all-patient refined diagnosis related group (APR-
DRG) measure of the expected risk of inpatient mortality. The 
APR-DRG uses diagnosis and procedure codes to estimate the 
likelihood of dying during the hospitalization as minor, moder-
ate, major, or extreme (25). The APR-DRG marker is not specific 
to stroke and does not include a measure of stroke severity. 
Hospital-level variables included geographic region (Northeast, 
Midwest, South, West), rural or urban location, status as a teach-
ing hospital (yes/no), and annual ischemic stroke case volume 
(<100, 100–299, ≥300).
statistical analysis
The statistical approach for this study parallels prior work from 
our group using the NIS to evaluate rt-PA use. Baseline char-
acteristics were described for patients treated at PSCs and non-
PSCs using measures of central tendency (means, medians) for 
continuous variables and proportions for categorical variables. 
Differences between the groups were evaluated using Student’s 
t, Wilcoxon rank-sum, and χ2 tests, as appropriate. Patients were 
stratified by sex, and then further stratified by race/ethnicity 
within sex. A multivariate model was constructed to determine 
independent associations including year of discharge, age, sex, 
primary expected payer, median income by ZIP code, hospital 
region, teaching status, urban/rural location, and ischemic stroke 
admission volume, the 29 Elixhauser comorbid conditions, and 
the APR-DRG measure of disease severity (20). Our analytic 
models used NIS survey statistics and Taylor series estimation 
to account for the survey design and clustering within hospitals. 
The analysis was conducted using SAS-callable-SUDAAN ver-
sion 11.0.1. As this was an exploratory analysis, no adjustments 
were made for multiple comparisons (26). An alpha of 0.05 was 
set as the level of significance.
resUlTs
Between 2004 and 2010, acute ischemic stroke was the primary 
diagnosis for 598,606 hospitalizations in the NIS. The inclusion/
exclusion criteria for the study population and the baseline 
patient- and hospital-level characteristics stratified by PSC 
status have been previously published (20). Table  1 describes 
the patient- and hospital-level characteristics for the sample, 
TaBle 1 | Patient and hospital characteristics stratified by sex.
Overall patient 
population
Male patients 
n = 141,841
Female patients 
n = 162,311
n = 304,152 (46.6%) (53.4%)
% % %
Evaluated at a primary 
stroke centera
24.7 25.4 24.1
race/ethnicitya
White 71.5 71.0 71.9
Black 15.0 14.4 15.5
Hispanic 7.9 8.6 7.4
Otherb 5.6 6.0 5.2
agea
18–44 3.9 4.3 3.6
45–64 25.1 31.4 19.6
65–80 37.7 40.0 35.7
>80 33.3 24.3 41.1
incomea,c
Lowest quartile 23.5 23.0 23.8
Second quartile 24.2 24.1 24.3
Third quartile 24.1 24.2 24.1
Highest quartile 26.0 26.1 25.8
Missing 2.3 2.6 2.0
Payment typea
Medicare 68.0 61.9 73.3
Medicaid 6.8 6.9 6.7
Private, incl. HMO 18.9 22.9 15.4
Self-pay 3.7 4.9 2.7
No charge 0.6 0.7 0.4
Other 2.0 2.6 1.5
hospital regiond
Northeast 30.9 30.6 31.1
Midwest 10.2 9.9 10.4
South 32.4 32.8 32.1
West 26.5 26.7 26.4
Rural hospital locatione 10.5 10.2 10.8
Teaching hospitala 41.1 42.1 40.3
ischemic stroke volumea
<100 (cases/year) 14.5 13.9 15.1
100–299 (cases/year) 46.6 46.2 46.9
≥300 (cases/year) 38.9 40.0 38.1
aχ2 test between males and females significant, p < 0.001.
bOther includes Asian/Pacific Islander, Native American, or other.
cMedian household income, by ZIP code.
dχ2 test between males and females significant, p = 0.003.
eχ2 test between males and females significant, p = 0.001.
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A lower proportion of women than men received rt-PA at 
both PSCs (6.8 vs. 7.5%, p < 0.001) and non-PSCs (2.3 vs. 2.8%, 
p < 0.001). Figure 2 shows treatment rates stratified by sex and 
race. A higher proportion of patients received rt-PA at PSCs in 
all sex and race/ethnicity groups. The proportion of rt-PA treated 
patients at PSCs ranged from 4.4% in black women to 8.1% in 
white men. The proportion of rt-PA treated patients at non-PSCs 
ranged from 1.9% for black women to 3.0% for white men.
In an unadjusted model, women were at lower odds of being 
treated with rt-tPA compared to men at both PSCs and non-PSCs 
(Table 2). After adjusting for year, age, primary expected payer, 
median income quartiles by ZIP code, region, teaching hospital, 
urban hospital location, annual ischemic stroke case volume, 29 
AHRQ individual comorbidities, and APR-DRG risk of mortal-
ity, the odds of being treated with rt-PA remained significantly 
lower for women regardless of presentation to a PSC (OR 0.87, 
95% CI 0.81–0.94) or non-PSC (OR 0.88, 95% CI 0.0.82–0.94). 
After stratifying by race, white women had significantly lower 
odds of rt-tPA treatment in the adjusted model (Table 2). In the 
multivariable model, sex did not modify the effect of PSC status 
on rt-PA utilization (p-value for interaction = 0.58).
DiscUssiOn
Our results illustrate that the relationship between PSC certifica-
tion and rt-PA utilization is similar in men and women. PSCs 
utilize rt-PA more than non-PSCs in both men and women, 
regardless of race/ethnicity. However, our results also illustrate 
that women are less likely to receive rt-PA than men at both PSCs 
and non-PSCs. In absolute treatment proportions, black patients 
are treated in lower proportions than other racial/ethnicity 
groups, and black women are treated less than any other group; 
however, the relative odds of treatment were lowest in white 
women relative to white men.
Sex disparities in the treatment of stroke remain a concern, 
particularly with the rise in incident stroke among women. 
IV rt-PA is effective for both men and women, but women may 
be even more likely to benefit from treatment than men (27, 28). 
Among patients not treated with rt-PA, women may have worse 
outcomes than men (29). It is therefore critical to ensure that 
women with stroke who are eligible for rt-PA receive treatment. 
PSCs administer more rt-PA than non-PSCs. This difference is 
equally true in men and in women. As more PSCs become cer-
tified throughout the US and as a greater proportion of stroke 
patients are evaluated at PSCs, IV rt-PA treatment in women 
should continue to increase. However, a better understanding 
of the drivers of sex differences in rt-PA treatment is needed 
to maximize the population benefit of developing systems of 
care and eliminate existing disparities. Identification of these 
drivers is of particular importance considering the evidence 
that rt-PA is associated with a greater improvement in stroke 
symptoms for women than for men, with no differences in 
adverse events after rt-PA administration between men and 
women (30, 31).
Lower rt-PA treatment rates in women may be related to 
patient factors. First, women tend to be older than men at the 
time of stroke. Second, women tend to present with more severe 
stratified by sex. Overall, 53.4% of the patients were women. 
Among women, 71.9% were white, 15.5% black, 7.4% Hispanic, 
and 5.2% were in other categories (e.g., Asian/Pacific Islander, 
Native American, other). Among men, 71.0% were white, 14.4% 
were black, 8.6% Hispanic, and 6.0% other. There were 75,160 
(24.7%) patients evaluated at a PSC, and 228,992 (75.3%) evalu-
ated at a non-PSC.
The proportion of patients evaluated at a PSC increased over 
time with similar proportions for men and women. The propor-
tion of racial/ethnicity groups presenting to a PSC stratified by 
sex increased over time (Figure 1). A little over half of the patients 
evaluated at PSCs were women (53.8%), with 71.5% of white, 
14.5% of black, 8.8% of Hispanic, and 5.3% of other patients 
evaluated at a PSC.
FigUre 2 | Proportion of men and women treated with rt-PA stratified by race/ethnicity and primary stroke center (PSC) versus non-PSC.
FigUre 1 | Proportion of patients presenting to a primary stroke center over time, stratified by sex and then by race/ethnicity.
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strokes (32). Third, knowledge of the signs and symptoms of 
stroke may be lower in women (14). This could potentially 
contribute to a delay in emergency department presentation, 
thereby preventing women from being treated if presentation is 
outside of the treatment time window (33). Unfortunately, the 
National Inpatient Sample does not contain the granular clinical 
data necessary to investigate these possibilities. More research is 
needed to determine why women are treated at a lower propor-
tion than men so that sex disparities in acute stroke therapies can 
be eliminated.
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Black women have the lowest proportion of rt-PA treatment, 
regardless of PSC status of the treating hospital. This finding sup-
ports prior data from two academic medical centers, which also 
found that black women were treated less frequently with rt-PA. 
In prior studies, black women were more likely to have delayed 
presentation, and once time from onset was accounted for, the sex 
and race disparity in rt-PA treatment no longer remained (19). 
It is possible that differences in time to presentation are respon-
sible for the findings in the present study, but as noted above, 
symptom duration is not available in the NIS.
This study has limitations similar to prior work evaluating 
rt-PA use in the NIS (7, 20). As this study relies on administrative 
claims data defined by ICD-9 codes, we were unable to determine 
if there were differences in rt-PA eligibility, stroke severity, or 
time to presentation. We do not have information on functional 
outcomes after rt-PA in this dataset and cannot assess sex differ-
ences in outcomes. States that do not provide data on hospital 
identity or race were excluded, including a few with large minor-
ity populations, such as Georgia and Texas. In spite of this, the 26 
states that provided data cover approximately 50% of the Hispanic 
and black population in the United States (34, 35). The definition 
of PSCs by TJC certification does not recognize other national 
or state-based certifications or identify hospitals that participate 
in national stroke care improvement programs, such as Get with 
the Guidelines. Misclassification of these hospitals as non-stroke 
centers would likely bias the results toward the null and would not 
change the observed disparities. The use of the ICD-9 procedure 
code 99.10 to define rt-PA may underestimate rt-PA use. This has 
the potential to introduce bias if coding varies between PSCs and 
non-PSCs or, less likely, between women and men (36). Finally, 
we are unable to investigate “drip and ship” cases. This could lead 
to underestimation of rt-PA utilization at non-PSCs.
cOnclUsiOn
The sex disparities seen in rt-PA utilization remain after account-
ing for race/ethnicity and other known factors that contribute 
to rt-PA underutilization. The increased utilization of rt-PA at 
PSCs is consistent between men and women and stable across 
racial and ethnic groups. Considering women may benefit from 
rt-PA utilization more than men, the disparity in utilization is 
concerning. Further research is needed to investigate what factors 
are contributing to this sex disparity.
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TaBle 2 | Odds of being treated with rt-PA for women, relative to men, at non-PSCs and primary stroke centers (PSCs), stratified by race/ethnicity.
sex non-Psc Psc
Unadjusted Or (95% ci) adjusted Or (95% ci) Unadjusted Or (95% ci) adjusted Or (95% ci)
Overall 0.83 (0.78–0.88) 0.88 (0.82–0.94) 0.88 (0.83–0.93) 0.87 (0.81–0.94)
By race/ethnicity
White 0.80 (0.75–0.85) 0.84 (0.78–0.90) 0.88 (0.82–0.94) 0.85 (0.78–0.93)
Black 0.90 (0.78–1.04) 0.99 (0.82–1.20) 0.84 (0.72–0.99) 0.96 (0.77–1.21)
Hispanic 0.92 (0.74–1.12) 1.04 (0.82–1.33) 0.87 (0.66–1.14) 0.85 (0.61–1.18)
Other 1.04 (0.80–1.35) 1.09 (0.77–1.53) 1.00 (0.81–1.24) 0.91 (0.67–1.25)
Adjusted for (where applicable): year, age, sex, primary expected payer, median income quartiles by ZIP, region, teaching hospital, urban hospital location, annual ischemic stroke 
case volume, 29 AHRQ individual comorbidities, all-patient refined diagnosis related group risk of mortality (minor, moderate, major, and extreme likelihoods of dying).
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